NCT06003400进行中（未招募）不适用
Proof of Concept Open Label, Clinical Trial to Evaluate the Safety and Efficacy of the "FITT" Device in Diabetic Foot Ulcers Patients
Tri.O Medical LTD2 个研究点 分布在 1 个国家目标入组 20 人开始时间: 2023年3月29日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 20
- 试验地点
- 2
- 主要终点
- Safety measured by number of patients who lack adverse events throughout the study.
研究概览
简要总结
The TriO FITT device is designed to improve the symptoms of chronic diabetic ulcers.
The mechanism of action of the device optimizes and combines the administration known supproting treatments to chronic diabetic ulcers. The treatment is astimated to improve the wound conditions of acute and chronic diabetic wounds.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Males and females 18-80 years old
- •Chronic Diabetes Mellitus type 1 and type 2 diagnosed at least 3 years before the screening
- •Have a single non-infected diabetic hard-to-heal wound (ulcers/foot ulcers) ≤ 0.8-40 cm2 wound area at start of treatment, for period of at least for 3 months.
- •Wagner classification stage 1 or 2 or post-debridement stage
- •At least moderate blood perfusion into the affected limb as defined by Ankle Brachial Index (ABI) ≥0.65
- •Stable diabetic drugs 4 weeks before Screening
- •Be available for the entire study period, and be able and willing to adhere to protocol requirements
- •Provide written informed consent prior to admission into the study
排除标准
- •Have a glycosylated hemoglobin (HbA1c) > 10.5%
- •Have more than one wound
- •Have a body mass index (BMI) > 40 kg/m2
- •Have visible bone exposure at wound site
- •Anemia (Hemoglobin < 9 g/dL) or White Blood Cells count > 11,000/μL or Platelets count < 100,000/μL or liver function tests > 3 times upper normal lab values or Creatinine > 3 mg/dL; any indication of malnourishment (Albumin < 3 g/dL); INR>2 or any other clinically significant blood and urinalysis tests per the physician's discretion
- •Patients with unstable hypertension
- •Have any clinically significant chronic or acute illness during the 4 weeks prior to admission into the study, except diabetes type 1 or 2 or during screening period
- •Females who are pregnant, lactating, of child-bearing potential, or post-menopausal for less than 2 years, not using a medically approved method of contraception (i.e., oral, transdermal, or implanted contraceptives, intrauterine device, diaphragm, condom, abstinence, or surgical sterility), or females who test positive on a urine-based pregnancy test
- •Participation in a clinical study or use of an investigational drug within 30 days prior to admission to this study
- •Patients with active Gangrenous foot ulcers
- •Active osteomyelitis (Have any signs of infection in the wound (which could be linked to raised body temperature), abscess, cellulitis, necrosis, erythema, mild drainage or known osteomyelitis)
- •Patients with uncontrolled hyperthyroidism
- •Patients with history of collagen diseases
- •Patients with known allergy to ozone
- •Anxiety, Depression, history of Mental illness or patient under Guardian
- •Any medical condition for which the investigator deems the subject unable to participate in the study
结局指标
主要结局
Safety measured by number of patients who lack adverse events throughout the study.
时间窗: 0 to 28 weeks
Change in pain level between visits 1 and the last treatment evaluated by VAS scale
时间窗: 0 to 28 weeks
pain levels will be measured by the precent of change in VAS pain raiting scale.
Change in Quality of life (QoL) between visits 1 and the last treatment, measured by SF-36
时间窗: 0 to 28 weeks
score measures from 0 to 100, 100 being good quality of life.
Change in wound size between V1 and the last treatment
时间窗: 0 to 28 weeks
change in size (cm\^2)
次要结局
未报告次要终点
研究者
研究点 (2)
Loading locations...
相似试验
已完成
早期 1 期
Placenta Derived Stem Cells for Treating of Chronic Ulcers and NeuropathyDiabetic NeuropathiesDiabetic Foot UlcerDiabetic FootNCT06373809Michael H Carstens20
已完成
不适用
Continuous Diffusion of Oxygen (CDO) Treatment for Healing of Diabetic Foot UlcersFoot Ulcer, DiabeticNCT02501538University of Texas Southwestern Medical Center23
已完成
不适用
Open study of TKKT01 for Diabetic UlcersJPRN-UMIN000035042ROHTO pharmaceutical CO.,LTD52
已完成
2 期
Trial in diabetic ulcer Using basic Fibroblast Growth Factor(KCB-1)Diabetic ulcerJPRN-UMIN000000831KAKEN PHARMACEUTICAL CO., LTD.150
已完成
不适用
Treatment of Diabetic Foot Ulcers With Inforatio Technique to Promote Wound HealingWound HealUlcer FootUlcer HealingDiabetic Foot UlcerDiabetic FootNCT03985306Zealand University Hospital12